After having trained in oncology at Harvard's Dana-Farber Cancer Institute, Dr. Druker then returned to the lab to begin his research career studying the regulation of the growth of cancer cells and the practical application to cancer therapies. His work was instrumental in the development of Gleevec, a drug that targets the molecular defect in chronic myeloid leukemia. After completing a series of preclinical studies, Dr. Druker spearheaded the highly successful clinical trials of imatinib for CML. Imatinib is currently FDA approved for CML and gastrointestinal stromal tumors. His role in the development of imatinib and its application in the clinic have resulted in numerous awards for Dr. Druker, including the John J. Kenney Award from The Leukemia and Lymphoma Society, the AACR-Richard, and many others.

Amir Dan Rubin serves as President and CEO of Stanford Hospital & Clinics in Palo Alto. He previously served as COO for the UCLA Hospital System, responsible for the operations of the Ronald Reagan UCLA Medical Center, Mattel Children's Hospital at UCLA, the Resnick Neuropsychiatric Hospital at UCLA, Santa Monica-UCLA Medical Center and Orthopedic Hospital, among others. Prior to UCLA, Amir served as COO for Stony Brook University Hospital where he was involved in efforts to improve quality, operations, and the patient experience. Prior to Stony Brook, Amir served as ASst. VP of Operations for Memorial Hermann Hospital in Houstons, and before that he was Director of Business Development for the corporate parent of the Memorial Hermann Healthcare System.

Dr. Aronson has overseen TEC’s development as a nationally recognized technology assessment program and an Evidence-based Practice Center (EPC) of the Agency for Healthcare Research and Quality (AHRQ). She has directed over 300 technology assessments and 20 evidence reports for AHRQ. Dr. Aronson is a member of the Methodology Committee of the Patient-Centered Outcomes Research Institute (PCORI), the Health Technology Assessment International Health Policy Forum, the Institute of Medicine Genomics Roundtable, the Steering Committee of the Chicago-Area DEcIDE Research Center, and the National Business Group on Health Committee on Evidence-Based Benefit Design. Previously, she has represented the private sector on a U.S. Agency for International Development Team providing technical assistance to the Hungarian government on building evidence-based medicine capacity and also served on the Ontario Health Technology Assessment Evaluation Review Team.

Since co-founding the company in 2000, Joff has served as Chief Scientific Officer and has overseen the research & development teams behind the breast, colon and prostate cancer programs. Joff and his team are currently deploying Next Generation Sequencing technology and its application across all research initiatives in an effort to connect either gene mutations or expression profiles to clinical outcomes and provide additional personalized information to physicians and patients beyond that already available through the use of Oncotype DX®. Prior to cofounding Genomic Health in 2000, he served as VP for Research Discovery at Genentech, Inc.. From 1993 to 2000, Joff oversaw Research Discovery at Genentech, which included the Departments of Cardiovascular Research, Oncology, Immunology, Endocrinology and Pathology. nsas.

Dr. Bready has served as CEO of NABsys since 2005. He led the acquisition of GeneSpectrum as well as the execution of the licensing deal with Brown University. Since joining NABsys, Barrett has been named one of the top "30 under 30" in New England. Barrett teaches "Biotechnology Management" at Brown University where he holds the position of Adjunct Assistant Professor of Biotechnology. He co-chairs BioGroup, Rhode Island’s biotechnology industry organization. Dr. Bready serves on the Board of Directors of the Brown Medical Alumni Association and is a Trustee of the Providence Preservation Society and WaterFire

Pierre Cassigneul is the President and Chief Executive Officer for XDx. He has more than 25 years of senior management experience in the healthcare and medical device industries, both in Europe and the U.S. He joined XDx from the consulting firm, Stone Bridge Management LLC, where he was an operating partner. Formerly, as the Vice President of Diabetes Management at Becton Dickinson & Co, he oversaw completion of the product, clinical trials and regulatory submissions. He has held top management positions at Bayer as well as Abbott Laboratories in the diagnostic division, where he launched the first HIV test for screening the European blood supply.

Dr. Dalton was the Founding Director of the Bone Marrow Transplant Program at the University of Arizona. In 1997 he was hired as the Associate Center Director for Clinical Investigations at H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida. While at Moffitt, he was appointed Deputy Director and was also the Professor and Founding Chairman of the Department of Interdisciplinary Oncology at the University of South Florida. Dr. Dalton returned to H. Lee Moffitt Cancer Center & Research Institute in August 2002 to serve as its Chief Executive Officer and Center Director.

Brett Davis is a Senior Director in Oracle's Health Sciences Global Business Unit, shaping and driving Oracle's personalized healthcare strategy and solutions.  He works closely with leaders in healthcare and life sciences to help them leverage innovative information technologies and applications to innovate and grow.  In addition to his role at Oracle, he is on the Board of Directors of the Personalized Medicine Coalition, and served on the US Department of Health and Human Services HRSA’s Genetic Services Policy Project Advisory Panel. Prior to joining Oracle, Brett was a Business Unit Executive in IBM's Healthcare and Life Sciences 

Dr. Steven Finkbeiner is an Associate Director and Senior Investigator at the Gladstone Institute of Neurological Disease. He is also a Professor of Neurology and Physiology at the University of California, San Francisco. He studies the molecular mechanisms that are responsible for learning, memory and neurodegeneration. He has served on the editorial board of BioMed Central and is a member of several scientific and professional societies, including the American Neurological Association, the Society for Neuroscience, the Society for Cell Biology and the Biophysical Society.

David Galas is Professor and Senior Vice President at the Institute for Systems Biology where he conducts his research, and leads multi-investigator projects. Formerly he was CSO for Life Sciences of the Battelle Memorial Institute. He was previously Chancellor, Chief Scientific Officer and Norris Professor of Applied Life Science at the Keck Graduate Institute of Applied Life Sciences, which he co-founded. Prior to that he served as President and Chief Scientific Officer of Seattle-based Chiroscience R&D, Inc. He has also served as Director for Health and Environmental Research at the U.S. Department of Energy's Office of Science, where he headed the DOE's Human Genome Project.

Dr. Gordon has over 20 years of experience in human brain research. He was the founding director of the Brain Dynamics Centre at Westmead Hospital, the CEO and Chairman of Brain Resource Company, and a senior lecturer in the Department of Psychological Medicine at the University of Sydney. He edited the first book on Integrative Neuroscience and has more than 250 peer-reviewed scientific publications. In 2003 he was the recipient of the inaugural Royal Societies Eureka Prize for Interdisciplinary Scientific Research.

Pat started his career in 1986 as a Research Scientist at Amoco Corporation. From 1987-1992 he was Manager Technical Support at GENE-TRAK Systems. He began his career with Abbott in 1992 as Manager, Technical Support in the Abbott Diagnostics Division and has held various positions at Abbott. From 1999-2000 he was Director of new product development for ADD in Germany. He was also responsible for Manufacturing Operations at ADD and then became Research Director and a Sr. Director of Manufacturing and Operations. He was promoted to a Divisional VP Quality and Operations and then became Divisional VP and General Manager, IBIS until his current position.

Dr. Hellerstein joined the faculty of the University of California at Berkeley in 1987. He maintains joint appointments in the Department of Medicine at the UCSF and at UC Berkeley, where he occupies an endowed chair. Dr. Hellerstein's major research interest has been the measurement in vivo of metabolic flux through pathways critical to health and disease. The great promise for applications of causal pathway flux metrics and network dynamic signatures to clinical diagnostics and drug development led directly to the founding of KineMed, Inc. in 2001.

Jamie entered the field of translational research and medicine when his brother Stephen was diagnosed with ALS at age 29. His innovations are transforming biotechnology and pharmaceutical development, personalized medicine, and patient care. As co-founder and chairman of PatientsLikeMe, Jamie provides the scientific vision and architecture for its patient-centered medical platform, allowing patients to share in-depth information on treatments, symptoms and outcomes. In 1999, he founded the ALS Therapy Development Institute, the world’s first non-profit biotechnology company and largest ALS research program.

Dr. Klemes has 10 years of experience working for Procter & Gamble in the areas of women's health and digestive wellness. Prior to her corporate career she was in private practice in endocrinology and metabolism. She has served as medical director of two diabetes centers and Chief of the Department of Medicine at Tallahassee Community Hospital, has done clinical research and has held leadership positions in the Florida Medical Association and the American Medical Association. She is a graduate of the New York College of Osteopathic Medicine and is board certified in internal medicine and endocrinology and is a Fellow of the American College of Endocrinology.

Dr. Kobashigawa is Associate Director of the Cedars-Sinai Heart Institute, Director of Advanced Heart Disease and Director of the Heart Transplant Program at Cedars-Sinai. In addition, he holds the DSL/Thomas D. Gordon Chair in Heart Transplantation Medicine. He is board certified in internal medicine and cardiovascular disease. He also is a clinical professor of medicine and cardiology at the David Geffen School of Medicine at UCLA. He lectures on cardiac transplantation at universities around the world, and works with young investigators in the Cardiology Fellowship Core Curriculum.

Dr. Koch has been in his current role of VP and Head of Global Research for Roche Molecular Systems since 2005. As a member of the Executive Leadership Team, he sits on the Life Cycle and Business Development committees, and chairs the Research Portfolio Committee. He is responsible for all RMD research and early development activities, including research efforts associated with biomarker discovery and validation, the development of new platform technologies, and fundamental improvements in the performance of existing products and technologies. He joined RMS in 1998 as a Research Leader and helped lead the launch of the AmpliChip CYP450 assay.

Dr. Landgren received his M.D. in 1995 from the Karolinska Institute (Stockholm, Sweden). Following clinical training as a hematology/internal medicine specialist physician and receipt of a Ph.D. focusing on diagnostics and prognostics in Hodgkin lymphoma (2002) at Karolinska Institute in Sweden, he worked as an attending physician and conducted clinical research on lymphoproliferative malignancies and related precursors. In 2004, he came to the National Cancer Institute, Genetic Epidemiology Branch, DCEG, where he worked as an Investigator before he joined the Medicial Oncology Branch. Dr. Landgren's major research interests are in the treatment, causation, diagnostics and prognostics, and natural history of multiple myeloma and its precursor condition, monoclonal gammopathy of undetermined significance (MGUS).

Dr. Mansfield is the Director of the Personalized Medicine Staff in the Office of In Vitro Diagnostic Devices in the Center for Devices, FDA, where she is developing a program to address companion and novel diagnostic devices.  She was previously a Senior Policy Analyst in the Office of In Vitro Diagnostic Devices (OIVD), managing policy and scientific issues. Dr. Mansfield formerly served as the Director of Regulatory Affairs at Affymetrix, Inc, 2004-2006.  She previously served in other positions at FDA including Scientific Reviewer, Genetics Expert. Dr. Mansfield received her PhD from Johns Hopkins University, and completed further postdoctoral training at the National Cancer Institute (NCI) and the National Institute for Arthritis, Musculoskeletal, and Skin Diseases (NIAMS).

Dr. Parkinson is President and CEO of Nodality, a South San Francisco-based biotechnology company. Until October 2007 Dr. Parkinson was Sr. Vice President, Oncology Research and Development at Biogen Idec, where he oversaw all oncology discovery research efforts and the development of the oncology pipeline. Previously he had served as Vice President, Oncology Development at Amgen and Vice President, Global Clinical Oncology Development at Novartis. He is a past Chairman of the FDA Biologics Advisory Committee and is a recipient of the FDA's Cody Medal. He has recently completed terms as a member of the FDA's Science Board and as an elected Director on the Board of Directors of the American Association of Cancer Research.

Dr. Patterson is an Executive Director in the Medical Sciences function at Amgen leading the In Vitro Diagnostic Group which is responsible for the identification, implementation and management of diagnostic partnering strategies for all Amgen therapeutics. He was previously VP of Proteomics at the Celera Genomics Group and the Chief Scientific Officer of Farmal Biomedicines, LLC. While at Celera, he established the company's initial foray into identification of cell surface targets for oncology, a number of which have been licensed. He was at Amgen from 1993–2000 ultimately leading the Department of Biochemistry and Genetics. His academic career began at The University of Queensland where he held research positions of increasing responsibility over a period of 11 years, culminating in that of Senior Research Officer.

Dr. Phelps is the Norton Simon Professor, Chair, Department of Molecular and Medical Pharmacology, and Director, Crump Institute for Molecular Imaging at UCLA, which he founded. Dr. Phelps is the inventor of the Positron Emission Tomography scanner and along his colleagues, developed a miniaturized pre-clinical PET scanner, microPET. He built a new combined basic and clinical science Department of Molecular and Medical Pharmacology at UCLA that includes PET and nuclear medicine clinical services, to bring together in vitro and in vivo molecular diagnostics and molecular therapeutics from cells and rodents to the care of patients. He also founded the translational science Institute for Molecular Medicine (IMED) at UCLA.

Dr. Polizzi is a Partner at Morrison & Foerster, where she helps emerging and established companies through the challenging process of obtaining patents, providing strategic, effective portfolio counseling and management. She develops valuable, strategic portfolios around breakthrough therapies in a variety of areas, including personalized medicine, cancer, autoimmune diseases, inflammatory diseases, infectious diseases, cardiovascular disease, metabolic disorders, and neurodegenerative diseases such as Alzheimer's Disease. Her practice also includes due diligence evaluation and counseling in the context of venture investment assessments, as well as in connection with public and private financing, spin-offs, partnerships, and mergers and acquisitions. Dr. Polizzi is recognized as one of the Top 25 IP managers in California for three years running.

Dr. Quinn practices within the firm's Government Strategies practice, where he focuses on Medicare coverage and payment matters for new technologies. Bruce is a national leader in the areas of Medicare coverage and payment, claims and billing, and Medicare contractor reform processes. He works with companies, providers and venture capital investors to develop strategies for Medicare payment for new technologies. A large part of this work is on local and national coverage decisions. Before serving in the Medicare Part B program, Bruce was a physician executive in the Health & Life Sciences division of Accenture and was a clinician-scientist at Northwestern University School of Medicine, leading pathology research for Northwestern's NIH-funded Alzheimer Research Center.

Stefan Roever has a broad entrepreneurial, software, and finance background. He was Co-Founder and CEO of Brokat Technologies, an encryption banking software company. Brokat reached a several billion dollar market cap and went public in 1998 on the Frankfurt Stock Exchange and on NASDAQ in 2000. Mr. Roever was honored with the Ernst and Young Entrepreneur of the Year Award in Germany. He is an active private equity investor and currently serves as Chairman of WRS Materials, a roll-up of wafer reclaim companies. Mr. Roever also is a two time award holder of Technology Pioneer by the World Economic Forum. He earned degrees in both economics and law from the University of Tuebingen.

Mr. Snelgrove brings to Crescendo Bioscience nearly 20 years of experience launching complex products in the healthcare field. As Vice President, Sales & Marketing for Genomic Health, he was responsible for commercialization of the Oncotype DX® Breast Cancer Assay. Prior to that, he worked for several leading biopharmaceutical companies, including ALZA, Amgen, Immunex and Eli Lilly, serving in a range of commercial positions from Sales to Marketing to Business Development. Mr. Snelgrove's professional career started as an officer with the U.S. Navy, where he flew helicopters and managed officer recruiting. He received an MBA in Marketing from the University of Michigan.

Dr. Snyderman is Chancellor Emeritus, Duke University and James B. Duke Professor of Medicine in the Duke University School of Medicine. He is currently a visiting professor in UCSF's Global Health Science Center. From 1989-2004, he served as Chancellor for Health Affairs and Dean of the School of Medicine, overseeing the development of the Duke University's Health System and serving as CEO. He is a proponent of "Prospective Care," where individuals receive personalized health plans. He is the recipient the Lifetime Achievement Award from the Arthritis Foundation and the first Bravewell Leadership Award.

Sharon Terry is President and CEO of the Genetic Alliance, a network transforming health by promoting openness and is founding CEO of PXE International, a research advocacy organization for the genetic condition pseudoxanthoma elasticum (PXE). Her memberships and advisories include the International Rare Disease Research Consortium and the Institute of Medicine Science and Policy Board. She was instrumental in the passage of the Genetic Information Nondiscrimination Act. Among other awards she received was the Clinical Research Forum and Foundation's Annual Award for Leadership in Public Advocacy in 2011.

Chris is currently the Founding Director and Chief Scientist at The Institute of Biomedical Engineering Imperial College, London, Founder and CEO of Toumaz Technology and Chairman and CEO of DNA Electronics. His career began with the invention and development of entirely novel concept of current-mode analogue circuitry for ultra-low-power electronic devices, amongst which was semiconductor-based DNA sequencing. In 2008, he was appointed the Fellowship of the Royal Academy of Engineering and the Fellowship of the Royal Society. Chris received the 2009 World Technology Award sponsored by Time Magazine for the Health & Medicine category.

Dr. Peter Paul Yu is in clinical practice and is also Director of Cancer Research at the Palo Alto Medical Foundation (PAMF), a multi specialty medical group serving the San Francisco Bay area.  Dr. Yu graduated from the combined undergraduate and medical school Program in Medicine at Brown University. Dr. Yu has served as co-chair of the Commission for Certification of Health Information Technology (CCHIT) Oncology work group, co-chair of the AMA-RAND Clinical Decision Support Oncology work group under contract to the Office of the National Coordinator for Health Information Technology and as co-chair of the ASCO-NCI CORE project.

Matthew Zubiller leads the company’s evidence-based decision support and personalized medicine initiatives. He drives operations, strategy, and product development for the Mckesson. He is a frequent speaker and author on topics such as next generation exception-based utilization management, decision support, and public policy for molecular and genetic testing. Previously, he ran McKesson’s Advanced Diagnostics Management business and was part of the corporate strategy team. His background includes diagnostics, healthcare, enterprise software, global strategy consulting and M&A. Recognized for his innovation, Mr. Zubiller was voted to Healthspottr’s “The Future of Health 100” list (ranked #49).

Mr. Bartz received his Ph.D. in Medical Microbiology and Immunology from the University of Wisconsin and continued his post-doctoral training at the Fred Hutchinson Cancer Research Center in Seattle. He joined Merck at the Rosetta Inpharmatics site, where his team developed siRNA screening platforms for identification of targets to support the early pipeline for Merck's disease area franchises. He later moved to the Merck Sirna site, where he led the Lead Development department in identifying and optimizing siRNA leads for use as RNA therapeutics. Most recently Steve joined Merck's External Scientific Affairs department as a Scientific Liaison supporting the West Coast activities.

Dr. Beresford is Vice President of Business Development and Strategic Marketing. His expertise includes leading groups that provide products and services to oncology-focused pharmaceutical and biotechnology companies for identifying and commercializing companion diagnostics. Prior to joining Biodesix, Dr. Beresford held a number of senior management positions at Ventana Medical Systems and Roche Diagnostics (after the acquisition of Ventana by Roche in early 2008) including Vice President, General Manager of Translational Diagnostics. He received a Ph.D. in Immunology from the Sackler School of Graduate Biomedical Sciences at Tufts University School of Medicine and was an Instructor and Junior Investigator at the Center for Blood Research at Harvard Medical School.

Ms. Borellini is currently Life Cycle Leader for Zelboraf at Genentech/Roche. She joined Genentech in February 2006, where she initially lead the development and life cycle plans for Tarceva® and Herceptin® in the US. She holds a PhD in Pharmaceutical Chemistry and Board Certification in Pharmacy from the University of Modena, Italy and completed her postdoctoral training at the NIDDK and NCI, working on regulation of cell growth/differentiation and mechanisms of multidrug resistance in cancer. Subsequently, she continued her work on multidrug resistance in cancer as a research Assistant Professor at Georgetown University.

Dr. Buckley is the Vice President, Core Sciences and Technology at Takeda California, where he is leading the Process Science function responsible for the CMC preclinical development of lead Ab candidates. Dr. Buckley has more than 20 years' experience in the biotechnology development and manufacturing sectors for both clinical candidates and commercially approved Monoclonal Antibody products. He has previously held executive positions with Neugenesis Corporation, Genitope Corporation and Corixa Corporation. At Corixa, Dr. Buckley was instrumental in the development of the first centrally manufactured radiopharmaceutical-Iodine-131 antibody (Bexxar(TM)).

Jim Burns has over 30 years of executive experience in the pharmaceutical, biotechnology, and diagnostic fields. He has served in leadership roles ranging from commercialization, financial, business development, and general management within businesses ranging from early-stage companies to large multinational corporations, venture capital, and private equity. Prior to joining AssureRx Health, Jim served as President and CEO of EntreMed, a public clinical-stage pharmaceutical company developing drugs for the treatment of cancer and inflammatory diseases; as President, EVP and a founder of MedPointe Pharmaceuticals, a specialty branded pharmaceutical company; a founder and Managing Director of MedPointe Capital, a private equity firm; President, CEO and a founder of Osiris Therapeutics; a founding General Partner of HealthCare Ventures LP, a venture capital partnership specializing in forming new pharmaceutical and biotech companies.

Mr. Butte is Chief of the Division of Systems Medicine and Associate Professor of Pediatrics, Medicine, and by courtesy, Computer Science, at Stanford University and Lucile Packard Children's Hospital. He studied computer science at Brown University, worked as a software engineer at Apple and Microsoft. He returned to Brown for his MD and trained in Pediatrics and Pediatric Endocrinology at Children's Hospital Boston. Thereafter, he received his PhD in Health Sciences and Technology from Harvard Medical School and MIT. Dr. Butte has authored more than 100 publications. His recent awards include the 2010 Society for Pediatric Research Young Investigator Award, induction into the American College of Medical Informatics in 2009, the 2008 AMIA New Investigator Award.

Bruce Cohen has spent more than 25 years in leadership positions in life science and high technology companies. He was the founding President and CEO of two early stage biotechnology companies: Cellerant Therapeutics and Acacia BioSciences. He also served as CFO for GeneSoft Pharmaceuticals prior to its merger into Oscient Pharmaceuticals. In addition, he held senior positions in business development and marketing at SEQUUS Pharmaceuticals and Baxter. Bruce was the President and COO of ViTel International, a privately held, pre-internet electronic messaging company and was a management consultant with Monitor Company, working in the health care and high technology sectors. He has an MBA from Harvard Business School, and a BA and MA from Tufts University. He was one of the founders of the Tufts Veterinary School and a co-founder of the Health Professions Information Bureau.

Dave Craford leads commercial operations at Pathwork, which includes sales, marketing, reimbursement, and customer support. He has 25 years of experience in the life sciences industry with a proven track record for building new markets and establishing market leadership. Prior to joining Pathwork, Mr. Craford was Vice President of Business Development at Affymetrix, Inc., where he held various business development and marketing leadership roles. Previously, Mr. Craford held senior sales positions with Amersham Life Sciences, Inc., and at BTX, a life sciences instrumentation company. Mr. Craford received a BA in biochemistry and cell biology from the University of California, San Diego, and an MBA with a focus on marketing and finance from the Haas School of Business at the University of California, Berkeley.

Ashley joined 23andMe in July 2011 as Chief Business Officer with global responsibility for the company's translational collaboration initiatives. Prior to joining 23andMe, Ashley was managing director at MPM Capital, a healthcare-dedicated venture capital firm where she spent eleven years advancing the work of innovative, entrepreneurial healthcare companies. Previously she was a healthcare equity analyst for Tiger Management and Dresdner RCM Global Investors. Dr. Dombkowski holds a PhD in Mathematics from Rice University and received a BA in Mathematics from Wellesley College.

David is an award-winning, best-selling author of seven books and numerous essays, articles and short stories; and a television, radio and film producer and correspondent. He writes columns for Fortune and for MIT Technology Review, and is the Chief Correspondent for public radio's "Biotech Nation". He writes for the New York Times, Wired, Discover, National Geographic, and many other publications. David's most recent book is the bestselling Experimental Man: What One Man's Body Reveals About His Future, Your Health, And Our Toxic World (Wiley). He wrote the international bestseller Calendar: Humanity's Epic Struggle to Determine a True and Accurate Year (Harper-Collins/Avon), published in 19 languages, and a bestseller in 14 countries.

Ronald Eisenstein is the co-leader of the firm’s Patent Interference, Opposition, Reexamination, and Reissue Team. Mr. Eisenstein focuses his practice in life sciences, including patent prosecution, interferences, oppositions, client counseling, transactional matters, due diligence, and patent litigation. Mr. Eisenstein has represented major U.S. research institutions, U.S. companies, and foreign corporations in handling interferences before the U.S. Patent and Trademark Office, which have involved personalized medicine, cancer vaccines, angiogenesis modulation, gene therapy, treatment of cancer, diagnostics, medical devices, immune modulation, disease biomarkers, diagnostics, signal transduction, and primate lentiviruses.

Pauline Farmer-Koppenol is an associate in the Intellectual Property Group of Fenwick & West LLP. Ms. Farmer's practice focuses on serving technology and life sciences clients in prosecuting patent applications, providing intellectual property strategy and counseling, and negotiating joint research agreements and patent licenses. Additionally, Ms. Farmer has analyzed patent portfolios for life science clients and investors.

Mr. Fineman has had multiple successes in starting and financing biomedical companies. In 1990, he co-founded SuperGen, Inc. (NASDAQ:SUPG). He led the SuperGen IPO as acting chief financial officer and served as a board member for eight years. He is a co-founder and board member of Quark Pharmaceutical, Inc. (QBI), a privately held biotechnology company, and served as its initial U.S. president. Mr. Fineman received his BA in 1966 from the University of Maryland and completed his MA in 1972 and PhD course work in 1974 in field theory at the Graduate Faculty of the New School for Social Research, where he was a university scholar.

As an expert on legal, ethical, and social issues surrounding health law and the biosciences, Hank Greely frequently serves as an advisor on state, national, and international policy issues. He is chair of California's Human Stem Cell Research Advisory Committee, the steering committee for the Stanford Center for Biomedical Ethics, a co-director of the Law and Neuroscience Project and directs the law school's Center for Law and the Biosciences. He also serves on the Scientific Leadership Council for the interdisciplinary Bio-X Program. Before joining the Stanford Law faculty in 1985, Greely was a partner at Tuttle & Taylor and served as a staff assistant to the secretary of the U.S. Department of Energy. Greely is also a professor (by courtesy) of genetics at Stanford School of Medicine.

Dr. Groskopf is the Director of Oncology Research and Development at Gen-Probe Incorporated. He received his Ph.D. in Molecular Biology from Northwestern University. He has 18 years of experience in molecular diagnostics and more than 15 peer-reviewed publications in cancer research. At Gen-Probe, he was the technical lead for the team that developed and commercialized the first molecular urine test for prostate cancer: PROGENSA® PCA3. Dr. Groskopf’s team is currently focused on research and development of assays based on prostate cancer gene fusions and other markers, and new instrument platforms to support next-generation tests for the detection and management of prostate cancer.

Ron Gutman, is the founder & CEO of HealthTap, the leading Interactive Health company that’s transforming the way people and physicians find, share and use personalized health information. Previously, Ron was the founder and CEO of Wellsphere, a leading online consumer health 2.0 company that developed the world’s largest community of health writers and became one of the largest health sites on the Internet. In health and technology, Ron is also an angel investor and advisor (Rock Health, Harvard’s SMArt Initiative), a frequent speaker (TED, Health 2.0, SXSW, Health Foo, and more…), and a published thought-leader (Forbes, Huffington Post). Ron also serves as Curator of TEDx Silicon Valley.

Jill Hagenkord joined Complete Genomics as Chief Medical Officer in August 2011. Previously, she founded iKaryos Diagnostics. Hagenkord served as an associate professor at Creighton and director of molecular pathology and clinical genomics. Dr. Hagenkord continues to serve on the iKaryos Board of Directors. Prior to joining iKaryos, Dr. Hagenkord worked as a pathologist for Deltagen, Inc. She received her MD from Stanford University School of Medicine and did her residency in pathology at UCSF and the University of Iowa. She completed fellowships in pathology/oncology informatics and molecular genetic pathology at the University of Pittsburgh.

Colin Hill has years of expertise in computational physics and systems biology. He serves as CEO and Chairman of GNS Healthcare’s parent company Via Science, chairman of the board of Fina Technologies, on the board of directors of several entities, including AesRx, Center for Applied Mathematics in Bioscience and Medicine, Emergent Behaviors of Integrated Cellular Systems, and the Exceptional Care Without Exception Trust. He has appeared in many publications and television segments including The Wall Street Journal, CNBC, Nature, Forbes, and The Economist. In 2004, Colin was named to MIT Technology Review’s TR100 list of the top innovators in the world under the age of 35. He earned master’s degrees in physics from McGill University and Cornell University.

Richard D. Hockett’s current position is Chief Medical Officer, Affymetrix, Santa Clara, CA.  His responsibilities include translation of genomics technologies, medical and regulatory affairs.  Special areas of focus are molecular diagnostics, clinical application of technology, and biomarker strategies.  Prior to joining Affymetrix, Dr. Hockett was a Medical Fellow II, Group Leader for Genomic Medicine at Eli Lilly and Company, where he developed the pharmacogenomic program and oversaw the application of genetic biomarkers to clinical drug development.  While there he was instrumental in developing the DMET analysis system.    Prior to joining Lilly, Dr. Hockett was employed by the University of Alabama at Birmingham in the Department of Pathology, where he oversaw the Clinical Immunology and Molecular Diagnostic Laboratories.  His research interests have been in the areas of Developmental Immunology and HIV disease.  Dr. Hockett received his M.D. degree from the University of Minnesota, and did his residency in Clinical Pathology at Washington University, St. Louis.

Matthew Hudes is U.S. Managing Principal, Biotechnology, for Deloitte's Life Sciences & Health Care practice. Previously, he was the Chairman and CEO of Acc'l're, a software company that developed a system to find patients for clinical trials and to improve researchers' access to information typically 'trapped' in laboratory and medical systems. Matthew has provided strategic professional services to leading biotechnology and pharmaceutical companies, including Amgen, Amylin, Biogen Idec, Chiron, Genentech, Johnson & Johnson, and Sanofi-Aventis. He speaks frequently about topics such as the use of technology for innovating clinical research, manufacturing, regulatory compliance, and supply chain.

Ann Kapoun is Vice President of Translational Medicine at OncoMed Pharmaceuticals. Her expertise is in the clinical execution and implementation of biomarkers and patient stratification approaches. Dr. Kapoun served as Associate Director of Biomarker R&D in Clinical Pharmacology & Experimental Medicine at ALZA / Johnson & Johnson. Prior to that she was the Department Head of Biomarker R&D at Scios Inc., where she was responsible for their Biomarker and Pharmacogenomics programs in support of clinical trials. Dr. Kapoun received her Ph.D. from Indiana University, Bloomington, IN, and she has co-authored more than 30 scientific publications and patents.

Walter Koch is the Vice President and Head of Global Research for Roche Molecular Systems. As a member of the Executive Leadership Team, he sits on the Life Cycle and Business Development committees, and chairs the Research Portfolio Committee. He joined RMS as a Research Leader to evaluate the feasibility of developing microarray-based pharmacogenetic assays for clinical diagnostic use, resulting in the launch of the AmpliChip CYP450 assay. Koch also served as the Senior Director of the Pharmacogenetics Department. Prior to joining Roche, he held several positions within the US FDA, including Acting Lab Chief of Immunochemistry and Research Biologist in the CEBR’s Division of Transfusion Transmitted Disease.

Dr. Lee leads business development strategies in clinical & translational informatics and personalized healthcare for Oracle's Health Sciences Global Business Unit. Prior to Oracle, Fred was the Founding Executive Director & Chief Medical Officer of the P4 Medicine Institute. He also led product strategy efforts for McKesson Corporation in its Provider Technologies division and has held leadership roles in General Electric Healthcare and as a COO and Chief Medical Information Officer of a large ambulatory care network in New York. He completed an MD and residency training from Stony Brook University School of Medicine, and a Masters in Public Health from Mailman School of Public Health at Columbia.

Mark Lee, MD, PhD is Senior Director, Oncology Development at Genomic Health. Dr. Lee earned his PhD in Biological Chemistry and Molecular Pharmacology at Harvard University, and his MD from Stanford University School of Medicine. He completed his internal medicine residency and medical oncology fellowship at Stanford, where he continues to serve as adjunct faculty. Prior to joining Genomic Health, Dr. Lee was part of the BioOncology Exploratory Clinical Development group at Genentech. At Genomic Health, he led the Colon Cancer Development team through the clinical validation study for the Oncotype DX Colon Cancer Assay, and currently oversees ongoing development efforts in colon and prostate cancer.

Julia Ortega McEachern heads up the Client Relations division at the Medco Research Institute (MRI) where she acts as the liaison between Medco clients, account executive teams and research teams. Prior to joining Medco she was with Ingenix where she headed up the Southeast region’s clinical effort in the area of improving Medicare Risk Adjustment scoring. Prior to her role at Ingenix, she also worked for United Health Group as a Clinical Advisor/Physician Assistant. Ms. McEachern’s clinical trials experience includes nine years of working in the area of Infectious Disease with NIH’s AIDS Clinical Trials Group and the Henry M. Jackson Foundation for the Advancement for Military Medicine.

Ms. Melin is Senior Manager, Business Development and Sales – North America for the BioSciences business unit of Sony DADC. Prior to joining Sony DADC, she was Director of Stanford Microfluidics Foundry. During this time, she successfully developed the foundry into an operation which manufactures polymer microfluidics devices for research institutes and universities. She received her Ph.D. in Microsystem Technology from the Royal Institute of Technology in Stockholm and M.B.A. from Northeastern University. Jessica has published numerous articles in areas including microfluidic large scale integration and logic, components and techniques for lab on chip devices, and cell biology.

Robert L. Michel is Editor In Chief of “The Dark Report” and  produces the Executive War College on Laboratory and Pathology Management. Mr. Michel has been quoted by The Wall Street Journal, New York Times, Associated Press, and other laboratory publications. He co-authored several major assessments of the laboratory industry and is frequently sought out as a strategic consultant by integrated hospital systems, commercial laboratories, pathology practices, and diagnostic manufacturers. He is a winner of the Newsletter and Electronic Publisher's Association prestigious "Best Investigative Reporting" Award and is listed in Marquis' Who's Who in Healthcare and Medicine.

Douglas Monroe is Project Manager for Biotechnology, Emerging Pharmaceutical Technology, and Specialty Pharmacy for Kaiser Permanente Drug Information Services (KP DIS) in the Regional Pharmacy Offices at Downey and Oakland, California. With a pharmacy background in hospital and clinical pharmacy practice, his work in Kaiser Drug Information involves evaluation of clinical trial evidence and development of evidence-based guidelines and usage plans for biopharmaceuticals, specialty pharmaceuticals, and pharmacogenomic testing. He has lectured on pharmacogenomics for the American and California Societies of Health-Systems Pharmacists and serves as an alternate member of the Institutes of Medicine Genomics Workshop.

Dr. Montgomery is an assistant professor in the Department of Pathology and the Department of Genetics at Stanford University. His lab focuses on understanding the mechanisms by which genetic variation influences cellular mechanisms and, ultimately, human traits. They utilize high throughput next generation sequencing to interrogate genomes and genome function in combination with utilizing and developing novel bioinformatics and statistical genetics tools. Dr. Montgomery's work has appeared in journals like Nature, Science and PLoS Genetics. He is the Director of Genome Informatics in the Department of Pathology and has been recently named by Genome Technology as one of twenty-five young investigators who are making their marks in the field of genomics.

Dr. Perkins is the CSO at the MMRF where she is responsible for the strategic development and execution of the MMRF's scientific agenda to accelerate the development of future treatments for myeloma. Prior to joining the MMRF, she was Director of Cancer Research at Bayer Pharmaceuticals, where she contributed to advancing novel targeted therapies toward clinical study, including Nexavar®. Prior to joining Bayer, she led a cancer research group at the Schering-Plough Research Institute. Dr. Perkins graduated from the University of Michigan with a PhD and MS in Biological Chemistry and conducted postdoctoral studies at Princeton University in the Department of Molecular Biology.

Ron began 25 years of experience in informatics as a physician, then as medical sales support at Eclipsys. Current projects include Kaiser Permanente’s National Clinical Information System and Intel’s healthcare provider segment and mobile point of care. Ron is a professor at the Rockefeller Center for e-Health, Kigali Institute of Science and Technology. Previously, he was a research fellow of Medical Informatics at Harvard, a visiting scientist of AI at IBM and Weizmann Institute and a clinical instructor at the Hebrew University. Committees include HIMSS Leadership Council and NIST National Medical Practice Knowledge Bank. Ron earned his M.D. degree from the Sackler School of Medicine, Tel-Aviv University.

As Executive Director and Head of Diagnostics, Hakan oversees Pfizer’s diagnostics needs across the R&D Portfolio. He received his BS and MS degrees from Ankara University in Turkey, and his PhD in Quantitative Genetics from the University of Minnesota as a Rotary Foundation Scholar. After conducting his postdoctoral studies at the University of California-Davis, he worked in the biotech industry in human genetics, pharmacogenomics and statistical genetics fields. Sakul’s last position was the Program Manager for the Xalkori (Crizotinib) Companion Diagnostics Development program, leading to simultaneous FDA approvals of both the drug and the companion diagnostic test.

Sambucetti serves as Senior Director of the Cancer Research Program, in addition to her work as Principal Investigator for SRI’s Comprehensive Screening Center for NCI’s Chemical Biology Consortium (CBC). Dr. Sambucetti is currently in the process of working with partners and the FDA to define a clinical path for an SRI exploratory drug entering Phase III as well as working to define development paths for our earlier stage cancer drug candidates. Previously, Sambucetti served as Director of Biochemistry at Telik, Inc., and led teams at Xenogen Corp. and Novartis, where she led a team that produced a cancer drug candidate currently in clinical trials.

Andrew Schorr is a respected medical journalist and online broadcaster who is a patient himself, a 14-year chronic lymphocytic leukemia survivor. Andrew participated in a phase II clinical trial for a 3-drug combination (chemotherapy+Rituxan) and it has led to a 10 year deep remission. He is a strong advocate for participation in clinical trials and founder and host of programs on www.patientpower.info on the latest treatments and research. Patient Power's sponsors include M.D. Anderson Cancer Center, Penn Medicine, University of Washington, UCSF Medical Center, Genentech, Amgen, and BioMarin.

Lisa Suennen is a co-founder and Managing Member of Psilos Group, a healthcare-focused venture capital firm with over $577 million under management. Lisa has headed Psilos' West Coast office since the firm's founding in 1998 and focuses on the medical device, healthcare information technology and healthcare services sectors. She serves as a Director on the Board of several Psilos portfolio companies. Lisa is also an active blogger. You can read her posts at www.venturevalkyrie.com.

Dr. Worthey is an Assistant Professor at the Human and Molecular Genetics Center and the Department of Pediatrics at the Medical College of Wisconsin. She received her MSc and PhD in Genetics from Birmingham University and Imperial College, London respectively. She is an expert in the fields of bioinformatics, genetics, and genomics. Worthey completed her postdoctoral fellowship in Genomics at the University of Washington at the Seattle Biomedical Research Institute. She is the first author on a recent groundbreaking paper detailing perhaps the first successful clinical application of next generation in diagnosing a sick child leading to a successful change in treatment.

Dr. Goldman is currently a Professor and Chair of the Department of Biology at San Francisco State University. His research is in chromatin structure and the regulation of gene expression during mammalian development, particularly the relationship between chromosome structural elements called nuclear matrix attachment regions as boundaries of functional chromatin domains. Goldman has written Op-Ed pieces featured in many publications, including the Los Angeles Times, as well papers published in Science and Nature Genetics. Thinking that the public learns much about science and bioethics from fiction, he reviews novels addressing various aspects of genetic science and its implications.

Dr. Kurtz has been a Program Director in the Small Business Innovation Research Development Center at the National Cancer Institute. His management portfolio includes projects focused on early-stage cancer drug development, including small molecules, biologics, and novel multifunctional therapeutics based on nanotechnology. Previously, Dr. Kurtz was an AAAS Science and Technology Policy Fellow at the NIH, during which time he served on the management team of The Cancer Genome Atlas Pilot Project. Dr. Kurtz received a PhD in Biochemistry & Molecular Biology from The University of Texas Medical Branch at Galveston.